EWTX
Edgewise Therapeutics, Inc.
$43.13
+3.03 (+7.56%)
At close · Jul 7
Market Cap
$4.64B
Shares
107,593,006
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$43.13
Open$40.50
Day$40.21–43.62
52W$12.30–43.93
Avg vol 30d1.5M
Short int9.9M · 9.2% float · 5.7d
Short vol60%
Last earningsMay 7, 2026
DataMar 2021–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.1 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+57%
above
Price vs 50-day avg
+22%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
97%
near high
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+21%
trailing
6-month return
+79%
trailing
YTD return
+74%
this year
Relative strength
+71%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $35 › 200d $27 — 50d above 200d
Institutional flow
Distributing
5 of 216 funds reported for Jun 30 · net -380 sh shares
Insider flow
Distributing
Net -$2.1M over 90 days · 100% sells
Short interest
Falling
9.23% of float · ▼ -9.0% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
216 holders — near 3-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
EPS growth
−12%
Y/Y
Free cash flow
$-144.1M
Balance sheet
$61.1M
net cash
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+57%
Bullish
Price vs 50-day avg
+22%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
97%
Bullish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $35 › 200d $27 — 50d above 200d
Institutional flow
Distributing
5 of 216 funds reported for Jun 30 · net -380 sh shares
Insider flow
Distributing
Net -$2.1M over 90 days · 100% sells
Short interest
Falling
9.23% of float · ▼ -9.0% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
216 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $12
Now $43 · 97%
52-wk high $44
vs 200-day avg +57%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EWTX
this stock
Edgewise Therapeutics, Inc.
|
$4.64B | +73.8% | — | — | 9.2% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EWTX | +5.5% | +21.2% | +78.7% | +6.2% | +73.8% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +4.6% | +19.8% | +71.2% | +6.0% | +64.2% |